Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
 Latest Headlines
•Brain tumor claims police canine Bandit (The Newark Post)
Thu, 19 Nov 2009 13:50:48 GMT
•World's First Delivery Of Intra-Arterial Avastin Directly Into Brain Tumor (Medical News Today)
Wed, 18 Nov 2009 17:40:11 GMT
•World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor (News-Medical-Net)
Wed, 18 Nov 2009 09:57:23 GMT
•World's first delivery of intra-arterial Avastin directly into brain tumor (Science Daily)
Tue, 17 Nov 2009 22:15:41 GMT
•Brain Tumor - Primary - Adults (New York Times)
Mon, 16 Nov 2009 21:38:24 GMT
•World's first delivery of intra-arterial Avastin directly into brain tumor (EurekAlert!)
Tue, 17 Nov 2009 15:29:08 GMT
•Patient Receives World's First Delivery of Intra-arterial Avastin Directly Into a Malignant Brain Tumor (Newswise)
Tue, 17 Nov 2009 15:57:32 GMT
•World's First Delivery Of Intra-Arterial Avastin Directly Into Brain Tumor (redOrbit)
Tue, 17 Nov 2009 21:10:37 GMT
•UCSF program shows house calls' time returning (San Francisco Chronicle)
Thu, 19 Nov 2009 14:54:39 GMT
•University College Hospital in London Introduces Treatments Delivering Faster Form of Radiotherapy (redOrbit)
Thu, 19 Nov 2009 16:10:01 GMT

* Headlines are from industry sponsored news wires, medical journals and established news organizations from around the world . Please consider the source of the content when viewing the story.
   
 
UCLA begins new Avastin Trials for Patients with grade IV GBM Tumor

UCLA Neuro-Oncology is sponsoring a Phase II trial which will further evalu­ate the safety and effectiveness of Avastin when taken alone or when taken in combination with Irinotecan a topoisomerase inhibitor. Irinotecan is also an FDA-approved drug for the treatment of certain other cancers that directly attacks and damages cancer cells. The study will also determine whether Avastin with or with­out Irinotecan can prevent or slow the growth of the tumor and lead to increase length of survival.

Improving clinical outcomes in glioblastoma brain tumors with genetic analysis

In this study, featured in the New England Journal of Medicine, glioblastomas patients who were treated with gefitinib or erlotinib, were found to be responsive to EGFR kinase inhibitors and strongly associated with coexpression by the tumor of EGFRvIII and PTEN.



UCLA Neuro-Oncology & SiliconMED Launch Online Tool Correlating Gene Expression Levels with Overall Survival of Brain Cancer Patients

Genomic analysis is a powerful new tool permitting unprecedented insights into how brain tumors form and has been enabled primarily through microarray technology. ProbeSetAnalyzer.com, a new web based tool, is aiming to help clinicians and researchers take the massive amount of data created by microarrays and better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.

Most Popular
.  Clinical Trials
.  Probe Set Analyzer
.  Our Team
.  Brain Tumor Translational Resource
.  Art of the Brain
.  Personalized Medicine using Targeted Molecular Therapy
.  Online Giving
.  How our Glioblastoma Multiforme Patients Perform

Spring / Summer 2009
Breakthroughs
BM-3-2009


Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Neurology
7;72(14):1217-22.

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
J Neurooncol.
183-9

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
J Neurooncol.
91(2):175-82

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
J Clin Oncol
26(34):5610-7

A tool for improving the longitudinal imaging characterization for neuro-oncology cases.
AMIA Annu Symp Proc.
712-6.

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2009 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2009 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:11/19/2009 7:12:21 PM PST]